STRASBOURG, France–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/Transgene?src=hash" target="_blank">#Transgene</a>–Regulatory News: Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, provides an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer. The independent Data Monitoring Committee (IDMC) of the PHOCUS trial has recommended to stop the study (see press release distributed on August 2, 2019). Transgene is currently analyzing the data of the trial it rec

Source link